Entering text into the input field will update the search result below

Global Blood Therapeutics - The Halloween 2017 Bioscience Stock

Nov. 01, 2017 3:20 AM ETPfizer Inc. (PFE)9 Comments


  • Global Blood Therapeutics can be a “trick or treat” investment to shareholders.
  • The stellar response of the single patient with SCD can foretell positive phase 3 trial.
  • Voxelotor can potentially capture peak sales ranging from $2B to $3B.

Global Blood Therapeutics (NASDAQ:GBT), a firm focusing on the innovation of medicine to treat blood disorders, made our featured presentation as the Halloween 2017 stock. Yesterday, the stock won our Bioscience Catalyst trade of the day, as it earned more than 10% profits for traders. The winning momentum extended into today’s trading: shares traded up $1.15 at $39.80 (for another 2.98% profits). As we previously mentioned, the new fortunes are due to the stellar pipeline development.

Source: Dr. Tran BioSci (Adapted from StockChart)

Accordingly, the firm reported robust response in the single patient (having moderate to severe symptoms associated with sickle cell disease) who has been treated with lead molecule GBT-440 (voxelotor). While the data on a single patient can indicate favorable results for the phase 3 Hope trial, the limited info can be difficult to gauge into upcoming fortunes. That being said, we’ll dissect the arguments for Global Blood Therapeutics for readers to gauge whether the firm is a trick or treat this Halloween.

Sickle Cell Disease

Affecting millions of people worldwide, SCD is a major health concern. According to Statistics from the CDC showed that there are 100,000 Americans living with the said condition (which occurs in 1 out of every 365 African-Americans, and 1 out of every 16,300 Hispanic-Americans). Prominently, SCD genes will always remain in the population, because “carriers” (those having the diseased plus normal genes) have other survival benefits. Most surprisingly, there is one carrier out of 13 blacks.

HbS (sickle hemoglobin) in its deoxygenated state is deformed (and it tends to clump together to form rods). Gradually, the deformed RBCs become stiff (causing a reduction in the blood flow). In addition, those sickled cells are easily degraded, thus leading to inadequate red blood cell level (or anemia).

The combinations of anemia and flow reduction

This article was written by

The #1 Biotech Service for Growth Investing and Catalyst Power Trading

As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading. 

Since inception, our flagship portfolio has delivered over 
31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.

Check out some of
our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.

In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis.
The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.

Follow us for the latest research. And,
take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!

Check out Dr. Harvey’s
LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.